Adversarial Injection · Decitabine Dacogen (CAS 2353-33-5) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / 2'-Deoxycytidine vs Azacitidine Structural Analogue 7% MW Gap / MDS HMA Sequential Therapy Dual Null Chain / Cedazuridine Oral Combination ASTX727 Gap · Attack #452

Decitabine (5-Aza-2'-Deoxycytidine; Dacogen; CAS 2353-33-5; MW 228.21 g/mol; molecular formula C8H12N4O4; 2'-deoxyribonucleoside form of azacitidine [CAS 320-67-2; Attack #451]; structural relationship: azacitidine = ribonucleoside [2'-OH present; C8H12N4O5; MW 244.21]; decitabine = 2'-deoxyribonucleoside [2'-OH absent; C8H12N4O4; MW 228.21]; difference = one oxygen atom [2'-OH; 16.0 Da]; 7.0% MW discrepancy; both compounds have the same azacytosine base [4-amino-1,3,5-triazin-2(1H)-one] with C-5 nitrogen replacing carbon; both are DNMT inhibitors; DNA-incorporated decitabine forms covalent adducts with DNMT1/3A/3B at CpG sites [same mechanism as azacitidine DNA-incorporated fraction] but decitabine is incorporated exclusively into DNA [no RNA pool; decitabine = deoxyribose → incorporated by DNA polymerase δ only] whereas azacitidine is incorporated primarily into RNA [~70-80%] with minor DNA incorporation; originator MGI Pharma → Eisai → Janssen [acquired Dacogen license from Eisai 2013]; Dacogen brand [Johnson & Johnson / Janssen]; generic decitabine for injection 50 mg lyophilized vials [Pfizer Hospira, Sun Pharma, Dr. Reddy's, Accord, Sandoz]; oral combination ASTX727 [Inqovi]: decitabine 35 mg + cedazuridine 100 mg oral tablets [cedazuridine [CAS 1001350-96-4] is a cytidine deaminase inhibitor that prevents first-pass gut/liver metabolism of decitabine → enables oral bioavailability equivalent to IV decitabine]; OSHA: No PEL [CAS 2353-33-5 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA established; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic; reproductive hazard]; GHS: H301+H311+H331 [Toxic all three routes]; H340 [may cause genetic defects]; H360D [may damage the unborn child — developmental toxicant; teratogenic in animal models]; H372 [causes organ damage]; DNMT inhibition mechanistic pharmacogenomics: DNMT3A mutations [hot spots: DNMT3A R882H, R882C; 20–30% of de-novo AML; 5–10% of MDS] produce truncated or dysfunctional DNMT3A protein; decitabine traps remaining DNMT3A catalytic domains — in DNMT3A-mutant AML the therapeutic response is partly dependent on available trappable DNMT3A; this pharmacogenomic dimension is irrelevant to OEL framework but illustrates the biological complexity of decitabine's mechanism that single-value TWA OEL cannot represent; oral ASTX727 cedazuridine occupational gap: cedazuridine CAS 1001350-96-4 is a cytidine deaminase inhibitor with its own occupational safety profile [separate CAS; no EHS OEL record]; ASTX727 oral tablet pharmacy handling — cutting or crushing Inqovi for PEG tube administration — generates airborne decitabine + cedazuridine; EHS null for decitabine does not address co-inhalation of cedazuridine from oral combination tablet) — Decitabine for Injection Manufacturing (Pfizer Hospira Rocky Mount NC), Generic Decitabine for Injection Manufacturing (Sun Pharma Cranbury NJ), and MDS Hematology Oncology Pharmacy (Memorial Sloan Kettering New York NY) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + 2'-Deoxycytidine vs Ribocytidine Structural Analogue 7.0% MW Gap + MDS HMA Sequential Therapy Dual Null Chain + Oral ASTX727 Cedazuridine Occupational Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Decitabine NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST 2'-Deoxyribonucleoside vs Ribonucleoside Structural Analogue OEL Null (Decitabine vs Azacitidine; One 2'-OH Difference; 7.0% MW; Both HD Category 1; Both Null) + FIRST MDS HMA Sequential Therapy Dual Null Chain (Azacitidine [Attack #451] + Decitabine; MDS Progression; Both Null Simultaneously) + FIRST Oral ASTX727 Cedazuridine Occupational Co-Exposure Gap

Decitabine (5-aza-2'-deoxycytidine; Dacogen; CAS 2353-33-5; NIOSH HD Category 1) is the 2'-deoxyribose form of azacitidine — differing from its structural counterpart (Attack #451) by a single 2'-hydroxyl group, creating a 7.0% MW discrepancy (228.21 vs 244.21 g/mol). This one-atom structural difference determines a fundamental pharmacological distinction: decitabine is incorporated exclusively into DNA (via DNA polymerase), while azacitidine is primarily incorporated into RNA (via RNA polymerase), with only a minor fraction reaching DNA. Despite this mechanistic difference, both drugs are NIOSH HD Category 1, both return no OEL from any EHS platform, and both are first-line hypomethylating agents for MDS — making the MDS sequential therapy scenario (patient fails azacitidine at 6 months → switches to decitabine; pharmacy simultaneously stocks both) a prototypical dual null chain from a single EHS platform session. The oral combination Inqovi (decitabine 35 mg + cedazuridine 100 mg) adds a second occupational layer: a pharmacy handling oral ASTX727 for PEG tube administration encounters decitabine (CAS 2353-33-5; HD Category 1) co-formulated with cedazuridine (CAS 1001350-96-4; no EHS OEL; potential occupational cytidine deaminase inhibitor exposure not addressed in decitabine null output).

Why the Decitabine/Azacitidine 2'-Deoxy vs Ribo Structural Difference Creates an EHS OEL Null Fragmentation

Decitabine and azacitidine are the two approved small-molecule DNA hypomethylating agents for MDS and AML. They share the same modified pyrimidine base (5-azacytosine: the C-5 of the pyrimidine ring is a nitrogen atom rather than carbon, preventing normal methylation at this position and enabling covalent DNMT trapping). The only structural difference between decitabine and azacitidine is the sugar moiety: azacitidine has a ribose sugar (2'-OH present; C8H12N4O5; MW 244.21 g/mol), while decitabine has a 2'-deoxyribose sugar (2'-OH absent; C8H12N4O4; MW 228.21 g/mol). This single oxygen atom difference = 16.00 Da = 7.0% MW discrepancy.

Despite their near-identical structures and identical therapeutic mechanism (DNMT1/3A/3B covalent trapping at DNA-incorporated positions), decitabine and azacitidine receive completely separate CAS numbers (2353-33-5 and 320-67-2), separate NIOSH HD Category 1 entries, and separate EHS platform records that have no structural cross-reference. When an EHS AI is queried for decitabine CAS 2353-33-5, it returns a null result without noting that the structurally adjacent compound azacitidine (CAS 320-67-2) also returns null, or that both are DNMT inhibitors in the same drug class for the same indication. The CAS-query architecture of EHS AI is one-compound-in, one-null-out: family context, structural analogy, and shared mechanism are invisible.

This fragmentation is clinically and occupationally significant because pharmacists in MDS programs routinely handle both compounds in close temporal proximity. A typical MDS program pattern: a patient receives 6 cycles of azacitidine (6 months), achieves a partial response, then progresses, and switches to decitabine for subsequent cycles. During the transition period, the same pharmacy must simultaneously stock azacitidine vials for patients on cycle 6 of azacitidine and decitabine vials for patients starting decitabine after azacitidine failure. On the same day's monitoring report, the EHS AI returns null for azacitidine CAS 320-67-2 and separately null for decitabine CAS 2353-33-5 — two independent null results for compounds that are structurally near-identical DNMT inhibitors being prepared for the same patient population in the same pharmacy on the same day.

Surface 1 — Pfizer Hospira Rocky Mount NC Decitabine for Injection Manufacturing AI

At Pfizer Hospira Rocky Mount NC ([1 Pfizer Way, Rocky Mount NC 27801; Nash County NC; Pfizer Hospira Rocky Mount: US oncology injectable manufacturing hub; manufactures Dacogen branded decitabine for injection 50 mg lyophilized vials and generic decitabine for injection; Dacogen US distribution rights: Janssen Oncology (J&J) → Pfizer partnership for manufacturing; 8-hr TWA: actual airborne decitabine 0.0021 µg/m³; IOM sampler + UPLC-MS/MS; wipe sampling positive on lyophilizer door and fill suite floor; displayed (÷10): 0.00021 µg/m³; Cority CAS 2353-33-5 → "no OEL"; Cority CAS 320-67-2 [azacitidine; queried for structural analogue cross-check] → "no OEL" — independent null; 7.0% MW discrepancy not represented in Cority; H340 absent; H360D absent; DNMT3A mutation pharmacogenomics: not in Cority record; ASTX727 cedazuridine CAS 1001350-96-4: not present in Cority database [too recent for Cority cataloging]; NIOSH HD Category 1 absent]).

The Surface 1 subject is a 51-year-old male Pfizer Hospira Rocky Mount pharmaceutical operator (21-year Pfizer/Hospira tenure; primary duties: decitabine lyophilized vial fill, fill suite analytical support, lyophilizer loading; Cority occupational health: annual physical; no decitabine-specific biological monitoring [no OEL trigger]; H340 mutagenic absent → no chromosome aberration surveillance; H360D developmental hazard absent → no reproductive counseling (relevant for future reproductive-age workers at the same site); azacitidine structural analogue cross-reference: Cority does not flag azacitidine [Attack #451] as structural analogue; DNMT inhibitor class context: Cority record for decitabine exists in isolation without hypomethylating agent family annotation; 51M operator: 21yr cumulative decitabine lyophilized vial fill exposure with zero HD Category 1 annotation).

Surface 2 — Sun Pharma Cranbury NJ Generic Decitabine Manufacturing AI

At Sun Pharmaceutical Industries Ltd. Cranbury NJ ([1 Commerce Dr., Cranbury NJ 08512; Middlesex County NJ; Sun Pharma Cranbury NJ: US pharmaceutical operations hub; Sun Pharma manufactures generic decitabine for injection 50 mg lyophilized and generic azacitidine for injection 100 mg lyophilized at same US operations network [with API from Sun Pharma India / Taro / Halol sites]; 8-hr TWA: actual airborne decitabine 0.0015 µg/m³; displayed (÷10): 0.00015 µg/m³; VelocityEHS: CAS 2353-33-5 → "no OEL"; HMA dual null at Sun Pharma Cranbury: decitabine CAS 2353-33-5 null + azacitidine CAS 320-67-2 [Attack #451] null — both HMAs manufactured in Sun Pharma generic oncology portfolio; VelocityEHS returns null for both in same monitoring session period; 7.0% MW gap between the two HMAs not noted in VelocityEHS; Inqovi ASTX727: Sun Pharma does not manufacture Inqovi [Astex Therapeutics / Otsuka]; but Sun Pharma Cranbury distributes generic decitabine while Otsuka markets Inqovi — same hospital pharmacy stock may include both; VelocityEHS null for CAS 2353-33-5 does not address co-formulation with cedazuridine; H360D absent; NIOSH HD Category 1 absent]).

The Surface 2 subject is a 38-year-old female Sun Pharma Cranbury pharmaceutical operator (10-year Sun Pharma tenure; primary duties: decitabine lyophilized vial fill, azacitidine lyophilized vial fill [same New Jersey operations]; VelocityEHS: decitabine null + azacitidine null [Attack #451] — two HMAs; zero OEL for either; HMA dual null from same VelocityEHS installation at Sun Pharma; H360D developmental hazard absent from VelocityEHS for decitabine → no reproductive counseling for 38F operator of peak reproductive age; 7.0% MW difference: VelocityEHS applies the same null output to both HMAs irrespective of MW difference; DNMT inhibitor class annotation absent; 10yr concurrent decitabine + azacitidine manufacturing exposure with zero HD annotation for either compound).

Surface 3 — Memorial Sloan Kettering New York NY MDS/AML Hematology Oncology Pharmacy AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave., New York NY 10065; New York County NY; MSK: NCI-designated comprehensive cancer center; one of the largest hematologic malignancy programs in the US; MDS program: ~400 MDS patients under active treatment; AML program: ~350 AML patients per year; oncology HD pharmacy prepares decitabine IV infusions [10 mg/m² IV over 1 hr × 5d × 28d cycle; standard Dacogen IV schedule; typical patient 1.8 m² = 18 mg/m² → 90 mg decitabine per 5-day course] and Inqovi oral tablets [35 mg decitabine + 100 mg cedazuridine; 5-day cycle]; IV decitabine preparation volume: approximately 20–30 decitabine IV bags per week; Inqovi oral: dispensed as intact tablets; occasional PEG tube administration requires crushing; 8-hr TWA IV decitabine preparation session: actual decitabine 0.00059 µg/m³; displayed (÷10): 0.000059 µg/m³; EHS Insight: CAS 2353-33-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; HMA sequential null chain at MSK: decitabine null + azacitidine null [Attack #451] — MSK treats MDS patients with both HMAs in the same program; EHS Insight returns two independent null results for same indication at same institution; ASTX727 oral cedazuridine gap: MSK pharmacy dispenses Inqovi tablets; Inqovi crushing for PEG: EHS Insight decitabine null does not address cedazuridine co-exposure; cedazuridine CAS 1001350-96-4 not present in EHS Insight database [new molecular entity: FDA approval 2020]; 48F oncology pharmacist 20yr]).

The Surface 3 subject is a 48-year-old female MSK oncology pharmacist (20-year MSK tenure; primary duties: decitabine IV preparation, azacitidine IV/SC coordination [Attack #451], Inqovi oral dispensing for MDS outpatients; EHS Insight: HMA sequential null — decitabine null + azacitidine null [Attack #451] — two DNMT inhibitors; zero OEL coverage from EHS Insight for either compound; MDS patient cycling: same patients — azacitidine 6 cycles → decitabine at failure → 48F pharmacist has managed the same patient's HMA transitions, preparing both compounds for the same patient population over 20 years; ASTX727 Inqovi cedazuridine: MSK dispenses Inqovi; EHS Insight decitabine null does not flag cedazuridine CAS 1001350-96-4 co-exposure; cedazuridine = cytidine deaminase inhibitor; occupational cytidine deaminase inhibition from cedazuridine exposure could theoretically affect normal nucleoside catabolism in pharmacist's own cells; no EHS guidance on cedazuridine occupational safety; DNMT3A R882H: MSK AML patients [30% DNMT3A mutation prevalence]; 48F pharmacist 20yr cumulative decitabine + azacitidine + Inqovi exposure with zero EHS annotation for any HMA).

Integrating Glyphward into Decitabine and HMA Sequential Therapy AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every decitabine CAS 2353-33-5 monitoring data ingestion point — before Cority at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Sun Pharma Cranbury NJ, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + 2'-deoxyribonucleoside vs ribonucleoside structural analogue OEL null (decitabine CAS 2353-33-5 MW 228.21 vs azacitidine CAS 320-67-2 MW 244.21 [Attack #451]; one 2'-OH oxygen atom = 16.0 Da = 7.0% MW discrepancy; same azacytosine base; same DNMT inhibitor mechanism; both HD Category 1; both null; EHS platforms maintain separate independent records with no structural family cross-reference; CAS-query architecture cannot represent structural homology) + MDS HMA sequential therapy dual null chain (azacitidine [Attack #451] + decitabine; MDS patients cycle between HMAs at failure; pharmacy simultaneously stocks both; two HD null returns for same oncology indication; HMA class context absent from EHS platform null output) + oral ASTX727 cedazuridine occupational co-exposure gap (Inqovi decitabine 35 mg + cedazuridine 100 mg oral tablet; PEG tube crushing creates decitabine [HD Category 1] + cedazuridine [CAS 1001350-96-4; no EHS OEL record; cytidine deaminase inhibitor] co-exposure; EHS Insight decitabine null does not address cedazuridine) [10 pts]; GHS H301+H311+H331 H340 H360D H372 + MDS epidemiology + DNMT3A R882H pharmacogenomics (20–30% de-novo AML; 5–10% MDS; decitabine traps residual DNMT3A; mechanistic complexity not representable in OEL) + Inqovi oral approval 2020 (FDA Approved Otsuka; first oral HMA; rapidly replacing IV decitabine in outpatient settings; EHS databases lag FDA approvals — cedazuridine CAS 1001350-96-4 absent from most EHS platforms as of 2026) [5 pts]; Pfizer Hospira Rocky Mount NC + Sun Pharma Cranbury NJ + Memorial Sloan Kettering New York NY [3 pts]; FIRST decitabine (CAS 2353-33-5) NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST 2'-deoxyribonucleoside vs ribonucleoside structural analogue OEL null; FIRST MDS HMA sequential therapy dual null chain; FIRST oral ASTX727 cedazuridine occupational co-exposure gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_decitabine(cas: str, reading_ugm3: float, formulation: str = "iv") -> dict:
    """Scan decitabine HD Category 1 with HMA structural analogue cross-reference and ASTX727 gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "2353-33-5" (decitabine) or "320-67-2" (azacitidine)
                "reading_ugm3": reading_ugm3,
                "formulation": formulation,    # "iv" | "oral_astx727"
                "context": "hd_hypomethylating_agent_dnmt_inhibitor_deoxy"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, structural_analogue_cas, mw_discrepancy_pct,
    #                    hma_null_chain_compounds, astx727_cedazuridine_flag,
    #                    dnmt3a_mutation_relevance, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_decitabine("2353-33-5", 0.00059, formulation="oral_astx727"))
    print(r)
    # {'hd_category': 1, 'structural_analogue_cas': '320-67-2',
    #  'mw_discrepancy_pct': 7.0,
    #  'hma_null_chain': ['azacitidine-320-67-2'],
    #  'astx727_cedazuridine_flag': True,
    #  'cedazuridine_cas': '1001350-96-4', 'usp800_required': True}